SignalSilence® YB1 siRNA IProduct information
SignalSilence® YB1 siRNA I
|300 µl (3 nmol)||
Product Pathways - siRNA
SignalSilence® YB1 siRNA I #6206
|6206S||300 µl (3 nmol)||---||In Stock||---|
|6206||carrier free and custom formulation / quantity||email request|
Product is assembled upon order. Please allow up to 1 week for your product to be processed.
Species predicted to react based on 100% sequence homology: Mouse, Rat.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® YB1 siRNA I (+) or SignalSilence® YB1 siRNA II #6207 (+), using YB1 Antibody #2749 and GAPDH (14C10) Rabbit mAb #2118. The YB1 antibody confirms silencing of YB1 expression and GAPDH (14C10) rabbit mAb is used to control for loading and specificity of YB1 siRNA.
SignalSilence® YB1 siRNA from Cell Signaling Technology (CST) allows the researcher to specifically inhibit YB1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products are rigorously tested in-house and have been shown to reduce target protein expression in specified cell lines.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM YB1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
The Y-box binding protein 1 (YB1) belongs to a family of evolutionarily conserved, multifunctional Y-box proteins that bind single-stranded DNA and RNA and function as regulators of transcription, RNA metabolism, and protein synthesis (1). YB1 binds to Y-box sequences (TAACC) found in multiple gene promoters and can positively or negatively regulate transcription. YB1 activates genes associated with proliferation and cancer, such as cyclin A, cyclin B1, matrix metalloproteinase-2 (MMP-2), and the multi-drug resistance 1 (MDR1) gene (2-4). YB1 represses genes associated with cell death, including the Fas cell death-associated receptor and the p53 tumor suppressor gene (5-7). It also interacts with the RNA-splicing factor SRp30c and stabilizes interleukin-2 (IL-2) mRNA upon induction of T lymphocytes by IL-2 (8,9). The majority of YB1 protein localizes to the cytoplasm, with a minor pool found in the nucleus; however, nuclear localization appears to be critical for its role in promoting proliferation. Nuclear translocation is cell cycle regulated, with YB1 protein accumulating in the nucleus during G1/S phase (2). In addition, nuclear translocation is induced in response to extracellular stimuli such as hyperthermia and UV irradiation, or treatment of cells with thrombin, interferons, or insulin-like growth factor (IGF-I) (2,10). Treatment of the MCF7 breast cancer cell line with IGF-I results in Akt-mediated phosphorylation of YB1 at Ser102, which is required for nuclear translocation of YB1 and its ability to promote anchorage-independent growth (10). Research studies have shown that YB1 is overexpressed in many malignant tissues, including breast cancer, non-small cell lung carcinoma, ovarian adenocarcinomas, human osteosarcomas, colorectal carcinomas, and malignant melanomas. Investigators have shown that nuclear YB1 expression correlates with high levels of proliferation, drug resistance, and poor tumor prognosis (2,7,10).
- Matsumoto, K. and Wolffe, A.P. (1998) Trends Cell Biol. 8, 318-23.
- Jurchott, K. et al. (2003) J. Biol. Chem. 278, 27988-96.
- Mertens, P.R. et al. (1997) J. Biol. Chem. 272, 22905-12.
- Uchiumi, T. et al. (1993) Cell Growth Differ. 4, 147-57.
- Lasham, A. et al. (2000) Gene 252, 1-13.
- Lasham, A. et al. (2003) J. Biol. Chem. 278, 35516-23.
- Homer, C. et al. (2005) Oncogene 24, 8314-25.
- Raffetseder, U. et al. (2003) J. Biol. Chem. 278, 18241-8.
- Chen, C.Y. et al. (2000) Genes Dev. 14, 1236-48.
- Sutherland, B.W. et al. (2005) Oncogene 24, 4281-92.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.